BioSpace News Archive

Drug Development

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

Blade Therapeutics, Inc. today announced receipt of feedback from the FDA regarding the company’s end-of-phase 1 data package for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for treatment of IPF and other fibrotic diseases.

April 4, 2022
·
14 min read
Business

Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors

Scorpion Therapeutics, Inc. today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors.

April 4, 2022
·
4 min read
BioMidwest

CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-Biofilm Technology for Life-Threatening Bacterial Infections

Clarametyx Biosciences Inc . today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development, has awarded the company an additional $3.89 million in option funding.

April 4, 2022
·
4 min read
FDA

GE Healthcare Receives FDA Approval of First-Ever Software to Help Automate Anesthesia Delivery and Reduce Greenhouse Gas Emissions During Surgery

GE Healthcare announced today the FDA pre-market approval (PMA) for its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System.

April 4, 2022
·
5 min read
BioMidwest

SecurAcath® Receives Innovative Technology Contract From Vizient

Interrad Medical, a privately held medical device company, announces its SecurAcath device has received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country.

April 4, 2022
·
2 min read
Drug Development

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented over the weekend at the American Academy of Neurology (AAN) annual meeting, held in Seattle, Washington.

April 4, 2022
·
10 min read
Genetown

Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring

Arch Therapeutics, Inc. today announced that two clinical case report abstracts of AC5 ® Advanced Wound System were accepted for Poster Presentations at the upcoming 2022 Symposium on Advanced Wound Care (SAWC) Spring.

April 4, 2022
·
5 min read
Genetown

Selecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare Conference

Selecta Biosciences, Inc. announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the 21st Annual Needham Virtual Healthcare Conference, to be held virtually April 11-14, 2022.

April 4, 2022
·
1 min read
BioForest

Nautilus Biotechnology to Present at EuPA and AACR Meetings

Nautilus Biotechnology, Inc. today announced presentations at the following leading scientific and medical conferences. XIV Annual Congress of the European Proteomics Association (EuPA).

April 4, 2022
·
4 min read
Genetown

Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Mustang Bio, Inc. today announced that members of Mustang’s management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022.

April 4, 2022
·
3 min read